Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06704724 · ClinicalTrials.gov registry record · Phase 1

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

A Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms, sponsored by Pfizer.

Active
Registry status
Phase 1
Development phase
30
Enrollment target
13
Study locations

NCT06704724 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 30 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (91% lower). The trial reports 13 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06704724, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms, is active but no longer recruiting, sponsored by Pfizer.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
13
Study locations

Study Summary

The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that: * are advanced (cancer that doesn't disappear or stay away with treatment) and * have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers). This includes (but limited to) the following cancer types: * Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body. * Colorectal Cancer (CRC): This is a disease where cells in the colon (a part of large intestine) or rectum grow out of control. * Pancreatic ductal adenocarcinoma (PDAC): This is a cancer that starts in the ducts of the pancreas but can spread quickly to other parts of the body. Pancreas is a long, flat gland that lies in the abdomen behind the stomach. Pancreas creates enzymes that help with digestion. It also makes hormones that can help control your blood sugar levels. All participants in this study will take the study medication (PF-07985045) as pill by mouth. This will be repeated for 21-day or 28-day cycles. Depending on which part of the study participants are enrolled into they will receive the study medication (PF-07985045 alone or in combination with other anti-cancer medications). These anti-cancer medications will be given in the study clinic by intravenous (IV) that is directly injected into the veins at different times (depending on the treatment) during the 21-day or 28-day cycle. Participants can continue to take the study medication (PF-07985045) and the combination anti-cancer therapy until their cancer is no longer responding. The study w

Conditions Studied

Carcinoma, Non-Small Cell Lung Colorectal Neoplasms Carcinoma, Pancreatic Ductal

Interventions

  • COMBINATION_PRODUCT Gemcitabine
  • COMBINATION_PRODUCT Nab-paclitaxel
  • COMBINATION_PRODUCT Cetuximab
  • COMBINATION_PRODUCT Fluorouracil
  • DRUG PF-07985045

Study Locations (13)

Arkansas

  • Highlands Oncology Group - Fayetteville
  • Highlands Oncology Group - Rogers
  • Highlands Oncology Group - Springdale

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Dana-Farber Cancer Institute - Boston
  • DFCI Chestnut Hill - Newton

New York

  • Columbia University Irving Medical Center - New York
  • The Trustees of Columbia University and The New York and Presbyterian Hospital - New York

Wisconsin

  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center - Madison
  • University of Wisconsin Carbone Cancer Center-University Hospital - Madison

California

  • City of Hope (City of Hope National Medical Center, City Of Hope Medical Center) - Duarte

Texas

  • The University of Texas MD Anderson Cancer Center - Houston

Other

  • Pan American Center for Oncology Trials, LLC - Rio Piedras

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-12-10
Est. Completion 2029-03-11
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06704724

The ClinicalTrials.gov registry entry for NCT06704724 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (91% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 5 interventions - of which Gemcitabine is the first listed.

NCT06704724 reports 13 study locations spanning 7 distinct geographic areas - top geographies include Arkansas, Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT06704724 about?

NCT06704724 is a clinical study titled "A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.". The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This st...

What is the current status of trial NCT06704724?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-12-10. Estimated completion is 2029-03-11.

What conditions does trial NCT06704724 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal.

What interventions are being tested in trial NCT06704724?

The interventions under investigation include: Gemcitabine (COMBINATION_PRODUCT), Nab-paclitaxel (COMBINATION_PRODUCT), Cetuximab (COMBINATION_PRODUCT), Fluorouracil (COMBINATION_PRODUCT), PF-07985045 (DRUG).

Who is sponsoring clinical trial NCT06704724?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06704724 being conducted?

This trial has 13 study locations across Arkansas, California, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Colorectal Neoplasms

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.